Anzeige
Mehr »
Dienstag, 25.08.2026 - Börsentäglich über 12.000 News
NurExone Biologic: Der CEO legt die Karten auf den Tisch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5F4 | ISIN: FI4000252127 | Ticker-Symbol: 4TS
Frankfurt
25.08.26 | 08:36
7,370 Euro
-1,60 % -0,120
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TERVEYSTALO OYJ Chart 1 Jahr
5-Tage-Chart
TERVEYSTALO OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
7,0808,51022:57
GlobeNewswire (Europe)
281 Leser
Artikel bewerten:
(1)

Terveystalo Oyj: Inside information, profit warning: Terveystalo lowers its guidance for 2026

Terveystalo Plc, Inside information, 15 July 2026 at 15:30 EEST

Terveystalo Plc lowers its guidance for 2026. The lowered guidance reflects the challenging demand environment in the first half of the year and profitability remaining below the level of the comparison period.

The demand environment in the first half of the year was very weak, which had a broad impact on the utilisation of services. In particular, in occupational health, volume development was negatively affected by a decrease in the number of connected employees compared to the comparison period, lower prevalence of upper respiratory infections, as well as cautious behaviour by corporate customers in an uncertain economic environment. Rare oversupply of resources in the industry has intensified price competition, which in turn has slowed new customer acquisition in occupational health and lowered the pricing level of new contracts. Weak demand development has been reflected across several businesses. However, early signs of stabilisation were seen in the market during the second quarter, particularly in consumer-driven services.

Guidance for 2026

Terveystalo expects its full-year 2026 adjusted operating profit (EBIT) to be EUR 120-140 million (2025: EUR 156.3 million).

Profitability in the first half of the year was clearly below the level of the corresponding period in 2025, and the demand environment was challenging. While the demand environment is still expected to gradually improve and the prevalence of upper respiratory infections is anticipated to return to long-term average levels during the second half of the year, the recovery in revenue and profitability is expected to lag the improvement in demand and therefore not fully materialise within the current year.

Revenue from outsourcing operations in the Portfolio Businesses segment is expected to decrease by approximately EUR 20 million due to expiring contracts. These estimates do not include the Hohde transaction, the acquisition of Silmäasema or any other significant acquisitions or divestments.

Guidance for 2026 provided in the Financial Statements Release on 13 February 2026:

Terveystalo expects its full-year 2026 adjusted EBIT to be EUR 135-165 million (2025: EUR 156.3 million).

The estimates are based on a gradually improving demand environment. The prevalence of upper respiratory infections is expected to remain low during the first half of the year and return to the long-term average in the second half. Profitability in the first half of 2026 is expected to be below that in the first half of 2025. Revenue from the Portfolio Businesses segment's outsourcing operations is projected to decrease by approximately EUR 20 million due to expiring contracts. These estimates do not include the Hohde transaction or any other significant acquisitions or divestments.

Preliminary information on Q2 2026

Terveystalo will publish its Half-Year Report for January-June 2026 on 17 July 2026.

Based on unaudited preliminary results, revenue for the second quarter of 2026 was approximately EUR 293.3 (321.5) million and adjusted operating profit (EBIT) was approximately EUR 26.1 (36.7) million, corresponding to approximately 8.9% (11.4%) of revenue.

Further information
CFO Juuso Pajunen
Tel. +358 40 584 9722

Terveystalo in brief

Terveystalo is the largest private healthcare service provider in Finland in terms of revenue and one of the leading occupational health providers in both Finland and Sweden.

We aim to create seamless, compassionate, and effective healthcare of the future. We offer comprehensive primary care, specialised care, and well-being services for corporate clients, insurance companies, consumers and public-sector customers. Terveystalo's digital appointments are available anytime, anywhere, 24/7. The Terveystalo app has around 2.7 million registered users. We provide services through our extensive network of clinics and hospitals across Finland. In Sweden, we offer preventive occupational health services through our subsidiary, Feelgood.

In 2025, Terveystalo served approximately 1.2 million individual customers, and there were around 7.2 million customer visits in Finland. Terveystalo employs around 14,400 professionals in healthcare and other fields.

Terveystalo is listed on Nasdaq Helsinki and has a strong Finnish ownership base. www.terveystalo.com

© 2026 GlobeNewswire (Europe)
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.